ESG Overview for FY 2025-26 submitted to exchanges
Sun Pharma has submitted its ESG Overview for FY2025-26, covering performance from April 1, 2025 to March 31, 2026.
- Report Period
- April 1, 2025 to March 31, 2026
- Reporting Boundary
- 44 manufacturing locations and R&D centres; 84% of operational sites for EHS indicators (~97% of revenues); 100% of sites for other…
- Company Revenues
- USD 6.6 billion
- Manufacturing Facilities
- 40 manufacturing facilities and 4 R&D centers across five continents
- Global Workforce
- 55,000+ employees across approximately 100 countries
What was shared
Sun Pharma submitted its ESG Overview for FY 2025-26 to NSE and BSE, stating it would be released after the submission. It covers ESG performance for the period April 01, 2025 to March 31, 2026.
Frameworks and assurance
- Developed with reference to the Global Reporting Initiative (GRI) Standards 2021, with a GRI Index appended.
- The company participates in S&P Global Corporate Sustainability Assessment (CSA), EcoVadis and CDP Climate Change and Water disclosures.
- Information has been externally assured by DNV Business Assurance India Private Limited.
Reporting boundary
- Comprises 44 manufacturing locations and R&D centres across national and international operations.
- 84% of operational sites for EHS-related indicators, representing about 97% of revenues; remaining sites account for about 3% of total revenue.
- 100% of operational sites for all other indicators, about 100% of revenues.
Company snapshot in the report
- Revenues of USD 6.6 billion.
- Medicines supplied in approximately 100 countries.
- 40 manufacturing facilities and 4 R&D centers across five continents.
- Total workforce worldwide of 55,000+.
- Headquartered in Mumbai.
Topics covered
The report spans corporate governance and ethics, business ethics, tax strategy, risk management, stakeholder engagement and materiality, product quality and safety, ethical clinical trials and marketing, access to healthcare, information security and responsible AI usage, energy, GHG emissions, waste, water, climate governance, biodiversity, environmental product stewardship, workforce wellbeing, human rights, employee health and safety, and sustainable supply chain.
How to read it
This is a periodic sustainability disclosure rather than a business transaction. It gives investors structured, externally assured information on environmental, social and governance practices alongside the company's financial reporting.
Also from Sun Pharmaceutical Industries
Board meeting on 12 October 2026 to consider NCD issuance of up to INR 15,000 Crore
7 Oct 2026
Announces $2.5 million endowed dermatology professorship at Mount Sinai
6 Oct 2026
LEQSELVI two-year data in severe alopecia areata shows sustained efficacy at EADV Congress 2026
1 Oct 2026
More numbers
- Manufacturing locations and R&D centres in reporting boundary44
- Operational sites covered for EHS indicators84%
- Revenue share covered for EHS indicators~97%
- Revenue share of excluded sites~3%
- Operational sites covered for other indicators100%
- RevenuesUSD 6.6 billion
- Countries of presence100
- Manufacturing facilities40
- R&D centers4
- Total workforce worldwide55,000+
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.